BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
Hims & Hers stock surged over 44% in premarket trading after a report said Novo Nordisk plans to sell its obesity drugs through the company’s telehealth platform.
Novo Nordisk stock plunged over 13% in premarket trading after its experimental obesity drug CagriSema failed to prove non-inferiority to Eli Lilly's tirzepatide in the REDEFINE…
Novo Nordisk stock jumped 8% after Hims & Hers withdrew its knockoff Wegovy pill amid FDA scrutiny and legal threats.
Novo Nordisk shares tumbled 18% after the company issued unexpectedly weak 2026 guidance, forecasting sales could decline as much as 13%.
Novo Nordisk stock moved higher after oral Wegovy logged over 18,000 first-week prescriptions, with Goldman Sachs boosting sentiment via a Buy rating.
Novo Nordisk shares rose nearly 5% in premarket trading after the company launched its Wegovy weight-loss pill in the U.S.
Novo Nordisk shares rose more than 7% in premarket trading after the FDA approved its oral Wegovy weight-loss pill.
Novo Nordisk shares fell in premarket trading after its phase 3 Alzheimer’s trials for semaglutide failed to show meaningful improvement over placebo.
Novo Nordisk stock jumped 4% in premarket after withdrawing from the Metsera bidding war, clearing the way for Pfizer's $10 billion acquisition.
Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, or a great opportunity?
Novo Nordisk stock crashed over 20% in premarket trading after the company cut its 2025 forecast for the second time.
Eli Lilly's new weight-loss pill, matches Ozempic in effectiveness.
Axon Enterprise saw its stock soar nearly 20% on strong AI service demand, while Lyft and Novo Nordisk shares plummeted due to disappointing financial results.